Biologics

Aug 28, 2015
By Pharmaceutical Technology Editors
Growth is said to be driven by the deeper penetration of biosimilars in developed and emerging markets as a result of clearer regulatory pathways.
Aug 24, 2015
Andrew Bulpin, executive vice president of EMD Millipore’s Process Solutions Business, speaks to Pharmaceutical Technology about the trends shaping the biopharmaceutical manufacturing industry.
Aug 17, 2015
The company adds a few new arguments—as well as new stakeholder support—to its Citizen Petition on biosimilar naming.
Aug 11, 2015
The Biosimilars Forum, along with numerous House members, advocated for the use of unique J-codes for biosimilars in a recent letter to CMS.
Aug 02, 2015
Pharmaceutical Technology
Potential for improved product quality and cost/time savings is reviving interest in perfusion technology.
Jul 30, 2015
The Generic Pharmaceutical Association and the Biosimilars Council wrote an open letter to President Barack Obama protesting the patent protections outlined in the Trans-Pacific Partnership.
Jul 27, 2015
FDA approved the drug for a more narrow indication in the US than did EMA for Repatha, Praluent’s fiercest competitor.
Jul 21, 2015
A Federal circuit appeals court ruled that a biosimilar manufacturer must wait six months after FDA approval to commercially launch its medication.
Jul 16, 2015
By Pharmaceutical Technology Editors
GSK accelerates delivery timeline for US quadrivalent flu vaccine.
Jul 06, 2015
By Pharmaceutical Technology Editors
Biogen plans to build a biologics manufacturing plant in northwest Switzerland using next-generation technologies to create efficiency and sustainability.